ConductScience.org, home

Paper6961970

Successful treatment of a patient with acute nonlymphoblastic leukemia (ANLL) and anthracycline cardiomyopathy with 4' (9-acridinylamino) methanesulfon-m-anisidide (AMSA).

Fanucchi MP and 1 other. Cancer Chemother Pharmacol, 1982. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Successful treatment of a patient with acute nonlymphoblastic leukemia (ANLL) and anthracycline cardiomyopathy with 4' (9-acridinylamino) methanesulfon-m-anisidide (AMSA). Papers, record 6961970. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6961970

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Successful treatment of a patient with acute nonlymphoblastic leukemia (ANLL) and anthracycline cardiomyopathy with 4' (9-acridinylamino) methanesulfon-m-anisidide (AMSA).
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
1982
PubMed
Publication types
Case Reports, Journal Article
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
0.36
iCite
Revised in PubMed
2019-08-29
PubMed

Authors2

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fanucchi MPM P
2Arlin ZAZ A

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AminoacridinesMajor topic
Antineoplastic AgentsMajor topic
Heart DiseasesMajor topic
LeukemiaMajor topic
Acute Disease
Adult
Amsacrine
Antibiotics, Antineoplastic
Digoxin
Female
Furosemide
Humans
Naphthacenes

Source PubMed

Download CSV of topics

References13

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
16946878A phase I and II study of m-AMSA in acute leukaemia.Cancer Chemother Pharmacol1981https://conductscience.org/library/papers/6946878PubMed
2496103Risk factors for doxorubicin-induced congestive heart failure.Ann Intern Med1979https://conductscience.org/library/papers/496103PubMed
321782The pharmacologic disposition of 4'-(9-acridinylamino)methanesulfon-m-anisidide in mice and rats.Drug Metab Dispos1977https://conductscience.org/library/papers/21782PubMed
46931630Acute ventricular fibrillation and death during infusion of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA).Cancer Treat Rep1980https://conductscience.org/library/papers/6931630PubMed
56945913Cardiac arrhythmia associated with AMSA in a child: a Southwest Oncology Group Study.Cancer Treat Rep1981https://conductscience.org/library/papers/6945913PubMed
6835599Daunomycin-induced cardiotoxicity in children and adults. A review of 110 cases.Am J Med1977https://conductscience.org/library/papers/835599PubMed
7759880Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography.N Engl J Med1979https://conductscience.org/library/papers/759880PubMed
8279397Phase 1 clinical investigation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (NSC 249992), a new acridine derivative.Cancer Res1978https://conductscience.org/library/papers/279397PubMed
96895190Treatment of acute leukemia in relapse with 4'(9-acridinylamino) methanesulfon-m-anisidide (AMSA) in combination with cytosine arabinoside and thioguanine.Cancer Clin Trials1981https://conductscience.org/library/papers/6895190PubMed
106933002Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia.Cancer Res1980https://conductscience.org/library/papers/6933002PubMed
11526933Neurologic and cardiac rhythm abnormalities associated with 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) therapy.Cancer Treat Rep1979https://conductscience.org/library/papers/526933PubMed
127212498Doxorubicin cardiotoxicity: assessment of late left ventricular dysfunction by radionuclide cineangiography.Ann Intern Med1981https://conductscience.org/library/papers/7212498PubMed
137307226Conference on long-term normal tissue effects of cancer treatment: summary of cardiac portion of cardiopulmonary workshop.Cancer Clin Trials1981https://conductscience.org/library/papers/7307226PubMed

Download CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn Papers
3568274Amsacrine treatment of patients with supraventricular arrhythmias and acute leukemia.Cancer Chemother Pharmacol1987https://conductscience.org/library/papers/3568274

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6961970

GET https://conductscience.org/api/papers/v1/6961970/authors